All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1300+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Eisai, Biogen gains Leqembi nod from Europe’s CHMP in limited Alzheimer’s population
Monoclonal antibody, Alzheimer’s disease - Read more

THE GOOD
Business Development

It’s the week for bispecifics as Merck & Co. buys global rights to LaNova Medicines LM-299; $588M upfront + $2.7B biobucks
Bispecific antibody, cancer - Read more

THE GOOD
Clinical Trials

Tune Therapeutics world-first epigenetic therapy in infectious disease TUNE-401 Ph1b cleared in New Zealand
mRNA, hepatitis B - Read more

GSK touts new survival data for Blenrep versus Johnson & Johnson’s Darzalex in multiple myeloma
Antibody-drug conjugate, multiple myeloma, cancer - Read more

Bristol Myers Squibb touts sustained responses in lupus using CAR-T therapy according to Ph1 data
Cell therapy, systemic lupus erythematosus, CAR-T - Read more

AC Immune positive interim Ph2 data for ACI-7104.056 in Parkinson’s disease
Vaccine, Parkinson’s disease - Read more

BioRestorative Therapies posts positive preliminary Ph2 data for BRTX-100 in chronic lumbar disc disease
Cell therapy, chronic lumbar disc disease, stem cell - Read more

Eli Lilly’s tirzepatide staved off full-blown diabetes in overweight/obese adults with pre-diabetes in latest Ph3 data haul
GLP-1, obesity, pre-diabetes - Read more

Curium’s ¹⁷⁷Lu-PSMA-I&T radiotherapy hits Ph3 primary endpoint in castration-resistant prostrate cancer trial
Radiopharm, prostrate cancer - Read more

Stayble Therapeutics touts positive Ph1b data for STA363 in lumbar disc herniation
Small molecule, lumbar disc herniation - Read more

PRESENTED BY YOU?
Get the attention of 1300+ Biotech & Pharma Professionals 🤩

Looking to promote your biotech/pharma/life science-focused product or service to a captivated audience of industry professionals?

Consider sponsoring TLDR Biotech - your sponsored feature would go right here!

If you want to see our prospectus or if you’re ready to work with us, just reply to this email or message me on LinkedIn.

⬇️ More Good News ⬇️

THE GOOD
Fundraises

Zai Lab $200M public offering
Small molecule, oncology, immunology - Read more

Aurealis Therapeutics CHF 8M ($9M) raise
Genetically engineered bacterium, chronic wounds, diabetic foot ulcer - Read more

Genesis Therapeutics equity raise from Nvidia
Small molecule, drug discovery platform, AI - Read more 

THE GOOD
IPOs

Telix Pharmaceuticals commences trading on Nasdaq stock exchange
Radiopharm - Read more

THE GOOD
Mergers & Acquisitions

Pulmatrix, Cullgen merger
Protein degrader, degrader-antibody conjugate, cancer - Read more

Advanced BioScience Laboratories (portfolio company of EW Healthcare) becomes part of Ascend Advanced Therapies
CDMO, fill-finish, oncolytic vector, viral vector - Read more

European Commission asks for feedback on Novo-Catalent deal
CDMO - Read more [Paywall]

THE GOOD
Partnerships

Novoprotein, Lumiere Therapeutic commercial partnership for enCas12Ultra gene-editing tool
Gene editing, commercialization - Read more

Amplia Therapeutics, Next&Bio preclinical drug screening collab
Small molecule, drug activity screening, cancer - Read more

ARTBIO, 3B Pharmaceuticals alpha radioligand research & licensing partnership
Radiopharm, solid tumor, cancer - Read more

TAE Life Sciences, Stella Pharma development, commercialization partnership for boronophenylalanine in boron neutron capture therapy in the USA and Europe
Small molecule, head & neck cancer, boron neutron capture therapy - Read more

THE GOOD
Research

Gene therapy gene too big? Just send them in two pieces and the cell can stitch them together, according to new research from University of Rochester
Gene therapy, Duchenne’s muscular dystropy, gene delivery, viral vector - Read more

THE GOOD
Strategic Plans

BeiGene proposes name change to BeOne Medicines
Cancer, oncology, name change - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Business Development

Innocoll Pharmaceuticals terminates Posimir license agreement with DURECT
Small molecule, post-surgical analgesia - Read more

THE BAD
Earnings & Finances

bluebird bio may run out of cash by Q1 2025
Gene therapy - Read more

Merck KGaA life science manufacturing unit sees continued business decline
CDMO, manufacturing, COVID-19 - Read more [Paywall]

THE BAD
Layoffs

Sensei Biotherapeutics closing Rockville, MD facility and cuts workforce by 46%
Monoclonal antibody, cancer - Read more

Gilead lays off 72 Seattle-based staffers
Small molecule, infectious disease, human immunodeficiency virus - Read more

THE BAD
Politics & Policy

Prominent vaccine skeptic RFK Jr. appointed to HHS top post (pending confirmation)
Public health policy, health and human services - Read more

THE BAD
Strategic Plans

Kronos ditches last clinical asset and begins the dreaded “explor[ation of] strategic alternatives”
Small molecule, ovarian cancer - Read more

Allogene Therapeutics chucks cema-cel leukemia plans after slowing trial enrolment due to “emergence of new alternative treatment options“
Cell therapy, leukemia, cancer, CAR-T - Read more

THE UGLY
Marketing

Merz Pharmaceutical instagram post slammed by FDA for “misleading [safety and effectiveness] claims”
Neurotoxin, wrinkles - Read more [Paywall]

THE UGLY
Patient Access

Novo Nordisk confirms global phase-out plans for insulin pen manufacturing
Insulin, diabetes, insulin pen - Read more [Paywall]

THE UGLY
Public Health

Totally preventable Measles cases rose worldwide by 20% in 2023 due to depressed vaccine uptake
Vaccine, measles, infectious disease - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here